Cargando…

Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies

Background: This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes. Methods: The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin...

Descripción completa

Detalles Bibliográficos
Autores principales: Stempkowska, Anna, Walicka, Magdalena, Franek, Edward, Naruszewicz, Marek, Panczyk, Mariusz, Sanchak, Yaroslav, Filipek, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716206/
https://www.ncbi.nlm.nih.gov/pubmed/33114431
http://dx.doi.org/10.3390/genes11111253
_version_ 1783619113670672384
author Stempkowska, Anna
Walicka, Magdalena
Franek, Edward
Naruszewicz, Marek
Panczyk, Mariusz
Sanchak, Yaroslav
Filipek, Agnieszka
author_facet Stempkowska, Anna
Walicka, Magdalena
Franek, Edward
Naruszewicz, Marek
Panczyk, Mariusz
Sanchak, Yaroslav
Filipek, Agnieszka
author_sort Stempkowska, Anna
collection PubMed
description Background: This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes. Methods: The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin 10 (IL-10) secretion in serum were assayed via ELISA tests. In the first part of the project, patients were divided into three groups which differed by the haptoglobin phenotype, and afterwards into two groups according to the criterion of the presence or absence of cardiovascular disease. Results: Diabetic patients with haptoglobin phenotype 1-1 (Hp1-1) had a significantly higher concentration of IL-10 and sCD163 compared to haptoglobin phenotype 2-1 (Hp2-1) and haptoglobin phenotype 2-2 (Hp2-2). Moreover, diabetic patients with Hp1-1 had a significantly lower concentration of p53 and HMGB1 compared to diabetic patients with Hp2-1 and Hp2-2. The results have shown that diabetics with Hp2-1 had a significantly lower postprandial glucose level compared to diabetics with Hp2-2. Apart from that, there were no differences in the occurrence of haptoglobin variants between patients with or without cardiovascular disease. Conclusions: Our study provides new data for a relationship between the type of haptoglobin in patients with type 2 diabetes and the concentration of factors that regulate the body’s inflammation. We have shown that the Hp1-1 can serve as a genetic marker of inflammatory processes.
format Online
Article
Text
id pubmed-7716206
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77162062020-12-05 Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies Stempkowska, Anna Walicka, Magdalena Franek, Edward Naruszewicz, Marek Panczyk, Mariusz Sanchak, Yaroslav Filipek, Agnieszka Genes (Basel) Article Background: This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes. Methods: The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin 10 (IL-10) secretion in serum were assayed via ELISA tests. In the first part of the project, patients were divided into three groups which differed by the haptoglobin phenotype, and afterwards into two groups according to the criterion of the presence or absence of cardiovascular disease. Results: Diabetic patients with haptoglobin phenotype 1-1 (Hp1-1) had a significantly higher concentration of IL-10 and sCD163 compared to haptoglobin phenotype 2-1 (Hp2-1) and haptoglobin phenotype 2-2 (Hp2-2). Moreover, diabetic patients with Hp1-1 had a significantly lower concentration of p53 and HMGB1 compared to diabetic patients with Hp2-1 and Hp2-2. The results have shown that diabetics with Hp2-1 had a significantly lower postprandial glucose level compared to diabetics with Hp2-2. Apart from that, there were no differences in the occurrence of haptoglobin variants between patients with or without cardiovascular disease. Conclusions: Our study provides new data for a relationship between the type of haptoglobin in patients with type 2 diabetes and the concentration of factors that regulate the body’s inflammation. We have shown that the Hp1-1 can serve as a genetic marker of inflammatory processes. MDPI 2020-10-24 /pmc/articles/PMC7716206/ /pubmed/33114431 http://dx.doi.org/10.3390/genes11111253 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stempkowska, Anna
Walicka, Magdalena
Franek, Edward
Naruszewicz, Marek
Panczyk, Mariusz
Sanchak, Yaroslav
Filipek, Agnieszka
Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies
title Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies
title_full Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies
title_fullStr Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies
title_full_unstemmed Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies
title_short Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes—Cohort Studies
title_sort hp1-1 as a genetic marker regulating inflammation and the possibility of developing diabetic complications in patients with type 2 diabetes—cohort studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716206/
https://www.ncbi.nlm.nih.gov/pubmed/33114431
http://dx.doi.org/10.3390/genes11111253
work_keys_str_mv AT stempkowskaanna hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies
AT walickamagdalena hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies
AT franekedward hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies
AT naruszewiczmarek hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies
AT panczykmariusz hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies
AT sanchakyaroslav hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies
AT filipekagnieszka hp11asageneticmarkerregulatinginflammationandthepossibilityofdevelopingdiabeticcomplicationsinpatientswithtype2diabetescohortstudies